We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.
Journal of Global Antimicrobial Resistance 2016 September
Here we report in vitro activity data from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) for tigecycline and comparators against Gram-positive and Gram-negative organisms collected from 27 medical centres in Spain between 2004 and 2014. Minimum inhibitory concentrations (MICs) were determined according to the broth microdilution methodology of the Clinical and Laboratory Standards Institute (CLSI) and susceptibility were determined according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretive criteria. Susceptibility was >97% for all antimicrobials tested against Enterococcus faecalis, and >98% of Enterococcus faecium tested were susceptible to tigecycline, linezolid and vancomycin. A total of 34.1% (1071/3143) of Staphylococcus aureus were meticillin-resistant S. aureus (MRSA), and all MRSA were susceptible to tigecycline and vancomycin. Among the Streptococcus pneumoniae, 5.2% (74/1430) were penicillin-resistant and all isolates were susceptible to linezolid and vancomycin. Among the Enterobacteriaceae, 17.1% (542/3167) of Escherichia coli, 2.8% (19/682) of Klebsiella oxytoca and 19.0% (441/2327) of Klebsiella pneumoniae isolates produced extend-spectrum β-lactamases (ESBLs). Against ESBL-producing E. coli and K. pneumoniae, susceptibility was highest for meropenem, amikacin and tigecycline with rates of >92% and >80%, respectively. Among the Acinetobacter baumannii, susceptibility ranged between 23.5% for levofloxacin and 51.4% for amikacin, and an MIC90 of 2mg/L was observed for tigecycline. In conclusion, monitoring of antimicrobial susceptibility among organisms such as S. aureus, Enterobacteriaceae and A. baumannii is of continuing importance as a guide to clinicians. Depending on the organism to be treated, carbapenems, linezolid, vancomycin and tigecycline continue to be active in Spain.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app